Chairs:  J. Cortes, T.P. Hughes, D. S. Krause
Organizers: R. Bhatia, M. Copland, M. Deininger, P. Hari, D. Perrotti, J. Radich, D. Réa

Strong basic and clinical science: Speakers at this meeting will present the newest and often unpublished data that relate to the (1) Biology of CML including the origin of BCR-ABL1, signal transduction, basis of disease progression, action of tyrosine kinase inhibitors and mechanisms underlying resistance to TKI, and (2) Aspects of treatment including prediction and definition of responses, drugs used in combination, modern diagnostics and molecular monitoring, targeting residual stem cells and approaches to cure.

CONTINUING MEDICAL EDUCATION (CME) ACCREDITATION:
CME for physicians and contact hours for allied health professionals will be provided through the Medical College of Wisconsin. This conference is also accredited by the European Hematology CME System (EBAH). Participants will be eligible to claim CME credit points.

EDUCATIONAL OBJECTIVES:
 Upon completion of this CME activity, participants should be able to:

• Understand current and new concepts of the signal transduction pathways involved in chronic myeloid leukemia (CML) and the mechanisms of action of tyrosine kinase inhibitors and other new agents.
• Have insight into the possible mechanisms of genomic instability that predisposes to formation of the BCR-ABL fusion gene and predispose also to disease progression and the consequences of such instability.
• Define a leukemia stem cell and its relationship to disease kinetics in so far as current knowledge permits.
• Evaluate the merits of various management decisions, e.g. how to start treatment for patients in the different phases of CML, how to assess success or failure of initial treatment, what approaches to consider for patients who have failed to respond well to initial treatment, including assessing the precise role of second and third generation TKIs and other non-molecular therapeutic approaches.
• Review the current recommendations and discuss current concepts and challenges of monitoring individual patients with hematologic, cytogenetic and molecular (RQ-PCR) methods.
• Assess the role of allogeneic stem cell transplantation in the management of CML.
• Critically evaluate the possible role of the different immunotherapeutic approaches in the treatment of CML.
• Discuss current data and ongoing research regarding treatment-free survival as an endpoint in CML management.
• Discuss patient reported outcomes and their role in the management of patients with CML.

THE PROGRAM WILL INCLUDE:
• John Goldman Prize
• Janet Rowley Prize
• iCMLf Prize
• Keynote lectures
• Special lectures
• Oral presentations selected from submitted abstracts
• Brief oral communications selected from submitted abstracts
• Workshops for non-clinical scientists
• Clinical and biology manned poster walks
• 2018 Symposium on Ph+/Ph-like ALL
• Concurrent Meet-The-Expert Sessions
• Opportunities for Satellite Symposia

For more info and to register:
http://www.esh.org/conference/20th-annual-john-goldman-conference-on-chronic-myeloid-leukemia-biology-and-therapy/